Speciality Medicines Ltd
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals.[1]
- Market Cap ₹ 168 Cr.
- Current Price ₹ 191
- High / Low ₹ 381 / 121
- Stock P/E 98.7
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| 23.18 | |
| 19.60 | |
| Operating Profit | 3.58 |
| OPM % | 15.44% |
| 0.02 | |
| Interest | 0.35 |
| Depreciation | 0.30 |
| Profit before tax | 2.95 |
| Tax % | 42.71% |
| 1.70 | |
| EPS in Rs | 4.45 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| -3.65 | |
| -0.12 | |
| 3.88 | |
| Net Cash Flow | 0.10 |
| Free Cash Flow | -3.73 |
| CFO/OP | -102% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Insights
In beta| Mar 2023 | Mar 2024 | Oct 2025 | |
|---|---|---|---|
| Chronic Diseases Share of Revenue % of revenue from operations ・Standalone data |
|
||
| Number of Customers Earning Revenue of ₹100 Lakhs or More customers ・Standalone data |
|||
| Number of Permanent Employees employees ・Standalone data |
|||
| Top 5 Customers Share of Revenue % of total revenue from operations ・Standalone data |
|||
| Number of Countries Exported countries ・Standalone data |
|||
| Number of Overseas Registered Products products ・Standalone data |
|||
| Number of Products in Portfolio products ・Standalone data |
|||
| Number of Products Under Process of Registration products ・Standalone data |
|||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no physical share certificates received for dematerialization.
-
Results - Financial Results For The Half Year And Year Ended March 31 2026
28 May - Board approved FY26 audited standalone results, unmodified audit opinion, and IPO proceeds utilization on May 28, 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E On May 28 2026
28 May - Board approved FY26 audited standalone results; profit rose to INR 1,303.29 lakh; IPO proceeds utilized INR 509.15 lakh.
-
Board Meeting Intimation for Meeting Of Board Of Speciality Medicines Limited To Be Held On May 28 2026
21 May - Board meets May 28, 2026 to approve FY26 audited standalone results; trading window closed from April 1, 2026.
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 19 May
Business Profile[1]
Co. is engaged in the marketing and distribution of specialty pharmaceutical formulations, with a focus on high-cost oral and injectable drugs across key therapeutic areas including oncology, immunology, neurology, and rare diseases.